Eric Duane Foster Sells 10,439 Shares of Ardelyx (NASDAQ:ARDX) Stock

Ardelyx, Inc. (NASDAQ:ARDX) insider Eric Duane Foster sold 10,439 shares of the firm’s stock in a transaction on Friday, February 20th. The stock was sold at an average price of $5.85, for a total value of $61,068.15. Following the sale, the insider owned 425,970 shares in the company, valued at $2,491,924.50. This trade represents a 2.39% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Ardelyx Stock Up 14.1%

Shares of NASDAQ ARDX opened at $6.56 on Wednesday. The stock has a market capitalization of $1.61 billion, a PE ratio of -26.24 and a beta of 0.57. The company has a quick ratio of 4.11, a current ratio of 4.31 and a debt-to-equity ratio of 1.21. The firm has a fifty day moving average of $6.77 and a 200-day moving average of $6.14. Ardelyx, Inc. has a 52-week low of $3.21 and a 52-week high of $8.40.

Ardelyx (NASDAQ:ARDX) last announced its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.03). Ardelyx had a negative net margin of 15.12% and a negative return on equity of 40.63%. The business had revenue of $125.22 million for the quarter, compared to analyst estimates of $118.04 million. During the same period last year, the firm earned $0.02 earnings per share. The company’s quarterly revenue was up 7.8% on a year-over-year basis. On average, analysts anticipate that Ardelyx, Inc. will post -0.18 EPS for the current year.

Institutional Investors Weigh In On Ardelyx

Hedge funds and other institutional investors have recently made changes to their positions in the business. DCF Advisers LLC acquired a new stake in Ardelyx during the second quarter worth $39,000. Brighton Jones LLC acquired a new position in shares of Ardelyx during the second quarter worth approximately $40,000. First Horizon Corp boosted its position in Ardelyx by 120.4% in the 4th quarter. First Horizon Corp now owns 7,906 shares of the biopharmaceutical company’s stock valued at $46,000 after buying an additional 4,319 shares during the last quarter. SBI Securities Co. Ltd. lifted its stake in shares of Ardelyx by 147.0% during the third quarter. SBI Securities Co. Ltd. now owns 10,253 shares of the biopharmaceutical company’s stock valued at $56,000 after acquiring an additional 6,102 shares during the period. Finally, Swiss Life Asset Management Ltd bought a new position in shares of Ardelyx in the 3rd quarter valued at about $57,000. 58.92% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Raymond James Financial reiterated a “strong-buy” rating and issued a $19.00 price target on shares of Ardelyx in a research note on Thursday, January 8th. HC Wainwright upped their price target on shares of Ardelyx from $10.00 to $18.00 and gave the stock a “buy” rating in a research report on Friday. Wedbush restated an “outperform” rating and issued a $19.00 target price on shares of Ardelyx in a research report on Monday. Jefferies Financial Group reiterated a “buy” rating and issued a $15.00 price objective on shares of Ardelyx in a report on Tuesday, January 27th. Finally, TD Cowen reiterated a “buy” rating on shares of Ardelyx in a research report on Thursday, January 29th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Ardelyx currently has a consensus rating of “Buy” and a consensus price target of $15.09.

Trending Headlines about Ardelyx

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Director David M. Mott bought 333,333 shares (~$1.95M) at about $5.84, increasing his stake ~11.2% — a strong insider vote of confidence that can support the stock. Read More.
• Positive Sentiment: Ardelyx announced a multi‑year partnership with the LPGA to raise awareness and reduce stigma around digestive health — a marketing push that could help commercial uptake of XPHOZAH/brand awareness over time. Read More.
• Positive Sentiment: Analyst support remains strong — Wedbush reaffirmed an outperform with a $19 target and other firms (BTIG, HC Wainwright, Jefferies, Citi) have reiterated buys or raised targets, which can attract buyers. Read More. Read More.
• Neutral Sentiment: Quarterly revenue beat estimates ($125.2M vs. $118.0M) and revenue grew ~7.8% y/y — constructive fundamental data but partially offset by the EPS miss.
• Neutral Sentiment: Post‑results commentary includes valuation and guidance analysis (coverage piece on Yahoo Finance reviewing 2025 results and 2026 guidance) — useful for longer‑term investors assessing upside vs. risk. Read More.
• Negative Sentiment: Ardelyx missed EPS expectations (reported a small loss vs. a modest expected profit), which triggered a post‑earnings pullback and adds short‑term risk for the shares. Read More.
• Negative Sentiment: Multiple insiders (including CEO Michael Raab, CFO Susan Hohenleitner and several executives) sold shares around Feb. 20 (CEO sold ~45,982 shares), which can be perceived as profit‑taking and may pressure sentiment despite the director buy. Read More.

About Ardelyx

Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.